Neovacs SA (FR:ALNEV) has released an update.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Neovacs SA, a French biotech firm focused on inflammatory and autoimmune diseases, has announced a capital reduction to offset losses by decreasing the nominal share value from 0.005 euro to 0.0005 euro. The company’s share capital now stands at 125,968.0985 euros, divided into 251,936,197 shares. Investors are cautioned about potential share dilution and capital loss due to the company’s dilutive financing operations.
For further insights into FR:ALNEV stock, check out TipRanks’ Stock Analysis page.